You have successfully sign out
Loading...
RenovoRx, Inc.
RNXT
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Â
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
1.21USD
-0.01Â ( -0.82%)
After-hours 1.15$-0.01 (-0.43%)Market Closed (as of Oct 08, 20:00 EDT)
Relative Strenght
30
Volume Buzz
27%
Earning Acce
No
Dist 52w H.
28%
